Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra

Neuroscience Letters

Volumn 329, Issue 3, 2002, Pages 354-358

  Feng, Z H ^a   Wang, T G ^b   Li, D D ^a   Fung, P ^a   Wilson, B C ^b   Liu, B ^b   Ali, Syed F ^c   Langenbach, R ^d   Hong, J S ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

1 Methyl 4 phenyl1, 2, 3, 6 tetrahydropyridine; Cyclooxygenase 2; Dopamine; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOPAMINE; HOMOVANILLIC ACID; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ELECTROCHEMISTRY; ENZYME ACTIVITY; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; WILD TYPE;

EID: 0037031609     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)00704-8     Document Type: Article

References (36)

1. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:(1):1994;27-34.
2. Bauer M.K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P.J., Bauer J., Fiebich B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243:(3):1997;726-731.
3. Bronstein D.M., Perez-Otamo I., Sun V., Mullis-Sawin J., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., McMillian M.K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704:1995;112-116.
4. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. 24:(Suppl. 49):1997;15-19.
5. Czlonkowska A., Kurkowska-Jastrzebska I., Czlonkowski A. Inflammatory changes in the substantia nigra and striatum following MPTP intoxication. Ann. Neurol. 48:2000;127-130.
6. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74:2000;2213-2216.
7. DeWitt D.L., Meade E.A., Smith W.L. PGH synthase isozyme selectivity: potential safer nonsteroidal anti-inflammatory drugs. Am. J. Med. 95:1993;40-44.
8. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;14669-14674.
9. Floyd R.A. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. 26:1999;1346-1355.
10. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J. Neural Transm. 7:1994;123-132.
11. Freyaldenhoven T.E., Cadet J.L., Syed F.A. The dopamine-depleting effects of 1-methyl-4-phenyl-1, 2, 3, 6-terahydropyridine in CD-1 mice are gender-dependent. Brain Res. 735:1996;232-238.
12. Freyaldenhoven T.E., Ali S.F., Schmued L.C. Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res. 759:1997;9-17.
13. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22:1999;219-240.
14. Heikkila R.E., Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int. 20S:1992;299-303.
15. Herschman H. Prostaglandin synthase 2. Biochim. Biophys. Acta. 1299:1996;125-140.
16. Hewett S.J., Uliasz T.F., Vidwans A.S., Hewett J.A. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. 293:2000;417-425.
17. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S., Ross M.E. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. USA. 98:2001;1294-1299.
18. Itzhak Y., Martin J.L., Ali S.F. Methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Synapse. 34:1999;305-312.
19. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156:1999;50-61.
20. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
21. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48:1984;87-92.
22. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1999;1403-1409.
23. McGeer P.L., Itagaki S., Boyes B.E., McGeer B.E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
24. Minghetti L., Walsh D.T., Levi G., Perry V.H. In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J. Neuropathol. Exp. Neurol. 58:1999;1184-1191.
25. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
26. O'Banion M.K. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin. Invest. Drugs. 8:1999;1521-1536.
27. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression in increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
28. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13:1998;35-38.
29. Raine C.S. Multiple sclerosis: immune system molecule expression in the central nervous system. J. Neuropathol. Exp. Neurol. 53:1994;328-337.
30. Ricaurte G.A., Irwin I., Forno L.S., Delanney L.E., Langston K.W. Aging and 1-methyl-4-phenyl-1, 2, 3, 6-terahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403:1987;43-51.
31. Rogers J., Civin W.H., Styren S.D., McGeer P.L. Immune-related mechanisms of Alzheimer's disease pathogenesis. Khachaturain Z.S., Blass J.P., Alzheimer's Disease, New Treatment Strategies. 1992;147-163 Marcel Dekker, New York.
32. Smith K.J., McDonald W.I. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;1649-1673.
33. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthase (cyclooxygenases)-1 and 2. J. Biol. Chem. 271:1996;33157-33160.
34. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 39:2001;167-174.
35. Vane J.R., Botting R.M. A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv. Prostaglandin Thromboxane Leukotreine Res. 23:1995;41-48.
36. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771.